TABLE 2.
Breast cancer subtypes classified by ER, PR, HER2, and Ki-67 expression.
| Subtype | Cell line | Origin | Research purpose | Sensitivity data |
|---|---|---|---|---|
| Luminal A | T47D | Human (ER+, PR+) | Hormone receptor response (Yu et al., 2017) | 1–3 mM (24 h): Viability↓(Liu H et al., 2021) |
| MCF-7 | Human (ER+, PR+) | Treatment response (Moon et al., 2020) | ≥1 mM (4–24 h), the IC50 = 4.5 ± 0.26 mM (Chang et al., 2014) | |
| Luminal B | BT-474 | Human (ER+, PR+, HER2+) | HER2-targeted therapy (Lasfargues et al., 1979) | 1–3 mM (24 h): Viability↓(Liu H et al., 2021) |
| HER2(+) | AU565 | Human (HER2+, HER3+, HER4+) | HER2 mechanisms (Schrörs, 2020) | 0.3 mM (24 h): Early viability↓(Liu H et al., 2021) |
| Basal like | MDA-MB-231 | Human (TNBC) | Metastasis mechanisms (Tseng et al., 2017) | 1–10 mM (4 h) Dose-dependent ↓(Jiang et al., 2016) |
| MDA-MB-468 | Human (TNBC; EGFR+) | Chemoresistance (Tseng et al., 2017) | 1–3 mM (24 h), Viability ↓ (Liu H et al., 2021) | |
| 4T1 | Mouse (TNBC-like) | In vivo metastasis & immunity (Schrörs, 2020) | 1.5–2 mg/kg/h, Reduced lung burden (Freeman et al., 2019) |
Abbreviations: ER, Estrogen Receptor; PR, Progesterone Receptor; HER2, Human Epidermal Growth Factor Receptor 2; TNBC, Triple-Negative Breast Cancer; IC 50, half-maximal inhibitory concentration.